Generic drug for nocturnal enuresis receives FDA approval
July 8, 2005
Barr Laboratories, Inc., has received final FDA approval to market a generic version of desmopressin acetate tablets, 0.1 mg and 0.2 mg, for the management of primary nocturnal enuresis.
Barr Laboratories, Inc., has received final FDA approval to market a generic version of desmopressin acetate tablets, 0.1 mg and 0.2 mg, for the management of primary nocturnal enuresis. The company said it is the first to file an abbreviated new drug application with the FDA for a generic version of desmopressin tablets and plans to launch its product immediately.
